Respiratory Motion Management Research Articles

AAPM Task Group Report 290: Respiratory motion management for particle therapy.

Dose uncertainty induced by respiratory motion remains a major concern for treating thoracic and abdominal lesions using particle beams. This Task Group report reviews the impact of tumor motion and dosimetric considerations in particle radiotherapy, current motion‐management techniques, and limitations for different particle‐beam delivery modes (i.e., passive scattering, uniform scanning, and pencil‐beam scanning). Furthermore, the report provides guidance and risk analysis for quality assurance of the motion‐management procedures to ensure consistency and accuracy, and discusses future development and emerging motion‐management strategies. This report supplements previously published AAPM report TG76, and considers aspects of motion management that are crucial to the accurate and safe delivery of particle‐beam therapy. To that end, this report produces general recommendations for commissioning and facility‐specific dosimetric characterization, motion assessment, treatment planning, active and passive motion‐management techniques, image guidance and related decision‐making, monitoring throughout therapy, and recommendations for vendors. Key among these recommendations are that: (1) facilities should perform thorough planning studies (using retrospective data) and develop standard operating procedures that address all aspects of therapy for any treatment site involving respiratory motion; (2) a risk‐based methodology should be adopted for quality management and ongoing process improvement.

Local control of stereotactic body radiotherapy with dynamic tumor tracking for lung tumors: a propensity score-matched analysis.

Dynamic tumor tracking (DTT) is a method of respiratory motion management in radiotherapy. It reduces the radiation field but risks delivering an insufficient radiation dose to the tumor. We investigated the local control of DTT-stereotactic body radiotherapy (SBRT) for lung tumors. Patients treated with SBRT for early-stage, non-small-cell lung cancer and lung metastases (2013-18) were retrospectively reviewed. Patients with tumor motion >1cm were treated with DTT-SBRT (DTT group); those with tumor motion ≤1cm were treated with static-SBRT (static group). A static planning target volume for the static-SBRT plan was also created for patients in the DTT group, and planning target volume reduction relative to the planning target volume for the DTT-SBRT plan was assessed. Patients were matched in a 1:1 ratio using a propensity score predictive of the SBRT technique. Of the 245 lesions in 218 patients (median follow-up, 25.4months), 69 were treated with DTT-SBRT and 176 with static-SBRT. The median planning target volume reduction in the DTT group was 30.3%. After propensity score matching, 124 lesions were included (62 per group). Two-year local control rates for the DTT and static groups were 94.2 and 95.9%, respectively, for all lesions (P=0.19) and 96.3 and 94.5%, respectively, for matched lesions (P=0.79). In univariate analysis, DTT-SBRT was not associated with local control for all lesions (hazard ratio, 2.06; P=0.20) or matched lesions (hazard ratio, 1.22; P=0.79). No grade 4/5 toxicities were observed. DTT-SBRT for lung tumors reduced the planning target volume, but not local control rates. DTT was useful for respiratory motion management.

A review of surface guidance in extracranial stereotactic body radiotherapy (SBRT/SABR) for set-up and intra-fraction motion management

IntroductionSurface guidance (SG) radiotherapy (RT) is now used by many radiotherapy departments globally and has expanded in popularity over the last number of years. A number of commercial systems are available. SG has routinely been used and is well established for cranial stereotactic radiosurgery (SRS) patient set ups and intra-fraction motion monitoring.However, data is limited in relation to its clinical use for extracranial stereotactic body radiotherapy (SBRT), particularly for targets which are impacted by respiratory motion such as the lung and liver.Objective & Information SourceA review of available literature was carried out on 24th October 2021 to assess the clinical feasibility and use of SG in SBRT via PubMed.MethodsEligibility CriteriaThe search criteria involved identifying articles where SG is used in extracranial SBRT.Risk of BiasTo eliminate the risk of bias, any particular commercial system was not the focus of the review and not included in the search criteria. Numerous clinical terms for similar things were used to reduce the risk of missing papers e.g. SBRT and SABR.Search CriteriaThe PRISMA checklist was used. Searching for “surface guidance and radiotherapy” yielded 3271 results, where as “SGRT” alone returned 72 results, when the search term was narrowed down using different iterations of SG and SBRT, only 6 results were available. Of these, 4 had reviewed clinical data in relation to SG and SBRT for patient set up and intra-fraction motion monitoring.ResultsThe 4 studies indicate positive results for using SG with sufficient image guidance (IG) for both patient set up and intra-fraction monitoring during SBRT. This was observed both in free breathing and in patients with respiratory motion management being employed such as deep inspiration breath-hold (DIBH) techniques. All used multiple IGRT solutions to verify localisation pre-treatment in conjunction with SG.LimitationsThe number of studies available which report using SG in SBRT is extremely limited. All centres had also installed SG systems therefore this could result in an unconditional bias in using the system positively.ConclusionSG can be used for SBRT set-ups and intra-fraction motion monitoring once sufficient IG is used to verify target localisation for treatment.

Comparison of T2 Quantification Strategies in the Abdominal-Pelvic Region for Clinical Use.

The aim of the study was to compare different magnetic resonance imaging (MRI) acquisition strategies appropriate for T2 quantification in the abdominal-pelvic area. The different techniques targeted in the study were chosen according to 2 main considerations: performing T2 measurement in an acceptable time for clinical use and preventing/correcting respiratory motion. Acquisitions were performed at 3 T. To select sequences for in vivo measurements, a phantom experiment was conducted, for which the T2 values obtained with the different techniques of interest were compared with the criterion standard (single-echo SE sequence, multiple acquisitions with varying echo time). Repeatability and temporal reproducibility studies for the different techniques were also conducted on the phantom. Finally, an in vivo study was conducted on 12 volunteers to compare the techniques that offer acceptable acquisition time for clinical use and either address or correct respiratory motion. For the phantom study, the DESS and T2-preparation techniques presented the lowest precision (ρ2 = 0.9504 and ρ2 = 0.9849 respectively), and showed a poor repeatability/reproducibility compared with the other techniques. The strategy relying on SE-EPI showed the best precision and accuracy (ρ2 = 0.9994 and Cb = 0.9995). GRAPPATINI exhibited a very good precision (ρ2 = 0.9984). For the technique relying on radial TSE, the precision was not as good as GRAPPATINI (ρ2 = 0.9872). The in vivo study demonstrated good respiratory motion management for all of the selected techniques. It also showed that T2 estimate ranges were different from one method to another. For GRAPPATINI and radial TSE techniques, there were significant differences between all the different types of organs of interest. To perform T2 measurement in the abdominal-pelvic region, one should favor a technique with acceptable acquisition time for clinical use, with proper respiratory motion management, with good repeatability, reproducibility, and precision. In this study, the techniques relying respectively on SE-EPI, radial TSE, and GRAPPATINI appeared as good candidates.

Application of Continuous Positive Airway Pressure for Thoracic Respiratory Motion Management: An Assessment in a Magnetic Resonance Imaging–Guided Radiation Therapy Environment

PurposePatient tolerability of magnetic resonance (MR)–guided radiation treatment delivery is limited by the need for repeated deep inspiratory breath holds (DIBHs). This volunteer study assessed the feasibility of continuous positive airway pressure (CPAP) with and without DIBH for respiratory motion management during radiation treatment with an MR-linear accelerator (MR-linac). Methods and MaterialsMR imaging safety was first addressed by placing the CPAP device in an MR-safe closet and configuring a tube circuit via waveguide to the magnet bore. Reproducibility and linearity of the final configuration were assessed. Six healthy volunteers underwent thoracic imaging in a 0.35T MR-linac, with one free breathing (FB) and 2 DIBH acquisitions being obtained at 5 pressures from 0 to 15 cm-H2O. Lung and heart volumes and positions were recorded; repeatability was assessed by comparing 2 consecutive DIBH scans. Blinded reviewers graded images for motion artifact using a 3-point grading scale. Participants completed comfort and perception surveys before and after imaging sessions. ResultsCompared with FB alone, FB-10, FB-12, and FB-15 cm H2O significantly increased lung volumes (+23%, +34%, +44%; all P <.05) and inferiorly displaced the heart (0.86 cm, 0.96 cm, 1.18 cm; all P < . 05). Lung volumes were significantly greater with DIBH-0 cm H2O compared with FB-15 cm H2O (+105% vs +44%, P = .01), and DIBH-15 cm H2O yielded additional volume increase (+131% vs +105%, P = .01). Adding CPAP to DIBH decreased lung volume differences between consecutive breath holds (correlation coefficient 0.97 at 15 cm H2O vs 0.00 at 0 cm H2O). The addition of 15 cm H2O CPAP reduced artifact scores (P = .03) compared with FB; all DIBH images (0-15 cm H2O) had less artifact (P < .01). ConclusionsThis work demonstrates the feasibility of integrating CPAP in an MR-linac environment in healthy volunteers. Extending this work to a larger patient cohort is warranted to further establish the role of CPAP as an alternative and concurrent approach to DIBH in MR-guided radiation therapy.

Dosimetric benefits of dynamic conformal arc therapy-combined with active breath-hold in lung stereotactic body radiotherapy.

To test the hypothesis that dynamic conformal arc therapy (DCAT) in Monaco, compared with volumetric modulated arc therapy (VMAT), maintains plan quality with higher delivery efficiency for lung stereotactic body radiotherapy (SBRT) and to investigate dosimetric benefits of DCAT with active breath-hold (DCAT+ABH), compared with free-breathing (DCAT+FB) for varying tumor sizes and motions. Fifty DCAT plans were used for lung SBRT. Randomly selected 17 DCAT plans were evaluated with respect to the retrospectively generated volumetric modulated arc therapy (VMAT) plans. The maximum dose at 2 cm from planning target volume (PTV) in any direction (D2cm/Rx), the ratio of 50% prescription isodose volume to the PTV (R50%), conformity index (CI), the lung volume receiving ≥20 Gy (V20), and monitor unit (MU) were evaluated. A t-test was used to evaluate the difference of plan quality between DCAT and VMAT. Internal target volume (ITV)/integrated-gross target volume (GTV) attributed by intra-fraction motion and lung V20 were stratified for DCAT+ABH and DCAT+FB across varying GTVs. DCAT maintained plan quality (p = 0.154 for D2cm/Rx, p = 0.089 for R50%, p = 0.064 for CI, and p = 0.780 for lung V20) while reducing MUs up to 30% (p <0.001) from 2748 MU (VMAT) to 1868 MU (DCAT). DCAT+ABH, compared to DCAT+FB, reduced tumor motion, resulting in 19% volume reduction of PTV and 60% reduction in lung V20, on average. The difference in lung V20 between DCAT+ABH and DCAT+FB increased as the target size increased. The DCAT is a favorable approach compared with VMAT. These results support the utility of DCAT as a routine planning platform for lung SBRT, especially when utilized with respiratory motion management using the ABH.

İleri Küçük Hücreli Olmayan Akciğer Kanserinde Split Kurs Radyasyon Tedavisi Alan Hastalarda Fiziksel Akciğer Doz-Hacim Parametrelerinin Değerlendirilmesi: Analitik Araştırma, Vaka-Kontrol

Objective: Active breathing control (ABC) system serves as a viable technique for the management of respiratory motion by providing reproducible breath-holding. Herein, we assess physical lung dose-volume parameters of V20 (total lung volume receiving ≥20 Gy) and mean total lung dose (MLD) in a series of patients receiving split course radiation therapy (SCRT) for advanced-stage non-small cell lung cancer (NSCLC) with the incorporation of the ABC system. Material and Methods: A series of 22 patients receiving ABC-guided SCRT for advanced-stage NSCLC were evaluated for physical lung dose-volume parameters of V20 and MLD. Two different radiation therapy plans have been generated for every patient with and without the incorporation of the ABC system to investigate the dosimetric impact. Results: Mean V20 and MLD were 32.3% and 2,104 cGy, respectively at freebreathing. Mean V20 and MLD were 24.7% and 1,697 cGy, respectively with the incorporation of the ABC system. The decrease in V20 and MLD was 23.53% and 19.34%, respectively. Conclusion: Our study shows improved normal lung tissue sparing by incorporation of ABC system in SCRT of advanced-stage NSCLC. The reduction in V20 and MLD may have clinical implications. Improved normal lung tissue sparing by use of the ABC system may result in an improved toxicity profile of radiation delivery and thereby enable dose escalation in selected patients. Admittedly, clinical follow-up of patients should be performed to elucidate clinical reflections of dosimetric gains achieved by the ABC system.

The markerless lung target tracking AAPM Grand Challenge (MATCH) results.

Lung stereotactic ablative body radiotherapy (SABR) is a radiation therapy success story with level 1 evidence demonstrating its efficacy. To provide real-time respiratory motion management for lung SABR, several commercial and preclinical markerless lung target tracking (MLTT) approaches have been developed. However, these approaches have yet to be benchmarked using a common measurement methodology. This knowledge gap motivated the MArkerless lung target Tracking CHallenge (MATCH). The aim was to localize lung targets accurately and precisely in a retrospective in silico study and a prospective experimental study. MATCH was an American Association of Physicists in Medicine sponsored Grand Challenge. Common materials for the in silico and experimental studies were the experiment setup including an anthropomorphic thorax phantom with two targets within the lungs, and a lung SABR planning protocol. The phantom was moved rigidly with patient-measured lung target motion traces, which also acted as ground truth motion. In the retrospective in silico study a volumetric modulated arc therapy treatment was simulated and a dataset consisting of treatment planning data and intra-treatment kilovoltage (kV) and megavoltage (MV) images for four blinded lung motion traces was provided to the participants. The participants used their MLTT approach to localize the moving target based on the dataset. In the experimental study, the participants received the phantom experiment setup and five patient-measured lung motion traces. The participants used their MLTT approach to localize the moving target during an experimental SABR phantom treatment. The challenge was open to any participant, and participants could complete either one or both parts of the challenge. For both the in silico and experimental studies the MLTT results were analyzed and ranked using the prospectively defined metric of the percentage of the tracked target position being within 2mm of the ground truth. A total of 30 institutions registered and 15 result submissions were received, four for the in silico study and 11 for the experimental study. The participating MLTT approaches were: Accuray CyberKnife (2), Accuray Radixact (2), BrainLab Vero, C-RAD, and preclinical MLTT (5) on a conventional linear accelerator (Varian TrueBeam). For the in silico study the percentage of the 3D tracking error within 2mm ranged from 50% to 92%. For the experimental study, the percentage of the 3D tracking error within 2mm ranged from 39% to 96%. A common methodology for measuring the accuracy of MLTT approaches has been developed and used to benchmark preclinical and commercial approaches retrospectively and prospectively. Several MLTT approaches were able to track the target with sub-millimeter accuracy and precision. The study outcome paves the way for broader clinical implementation of MLTT. MATCH is live, with datasets and analysis software being available online at https://www.aapm.org/GrandChallenge/MATCH/ to support future research.

An Evaluation of Total Internal Motions of Locally Advanced Pancreatic Cancer during SABR Using Calypso® Extracranial Tracking, and Its Possible Clinical Impact on Motion Management.

(1) Background: the aims of this study were to determine the total extent of pancreatic cancer’s internal motions, using Calypso® extracranial tracking, and to indicate possible clinical advantages of continuous intrafractional fiducial-based tumor motion tracking during SABR. (2) Methods: thirty-four patients were treated with SABR for LAPC using Calypso® for motion management. Planning MSCTs in FB and DBH, and 4D-CTs were performed. Using data from Calypso® and 4D-CTs, the movements of the lesions in the CC, AP and LR directions, as well as the volumes of the 4D-CT-based ITV and the volumes of the Calypso®-based ITV were compared. (3) Results: significantly larger medians of tumor excursions were found with Calypso® than with 4D-CT: CC: 29 mm (p < 0.001); AP: 14 mm (p < 0.001) and LR: 11 mm (p < 0.039). The median volume of the Calypso®-based ITV was significantly larger than that of the 4D-CT based ITV (p < 0.001). (4) Conclusion: beside known respiratory-induced internal motions, pancreatic cancer seems to have significant additional motions which should be considered during respiratory motion management. Only direct and continuous intrafractional fiducial-based motion tracking seems to provide complete coverage of the target lesion with the prescribed isodose, which could allow for safe tumor dose escalation.

Visually guided respiratory motion management for Ethos adaptive radiotherapy.

PurposeEthos adaptive radiotherapy (ART) is emerging with AI‐enhanced adaptive planning and high‐quality cone‐beam computed tomography (CBCT). Although a respiratory motion management solution is critical for reducing motion artifacts on abdominothoracic CBCT and improving tumor motion control during beam delivery, our institutional Ethos system has not incorporated a commercial solution. Here we developed an institutional visually guided respiratory motion management system to coach patients in regular breathing or breath hold during intrafractional CBCT scans and beam delivery with Ethos ART.MethodsThe institutional visual‐guidance respiratory motion management system has three components: (1) a respiratory motion detection system, (2) an in‐room display system, and (3) a respiratory motion trace management software. Each component has been developed and implemented in the clinical Ethos ART workflow. The applicability of the solution was demonstrated in installation, routine QA, and clinical workflow.ResultsAn air pressure sensor has been utilized to detect patient respiratory motion in real time. Either a commercial or in‐house software handled respiratory motion trace display, collection and visualization for operators, and visual guidance for patients. An extended screen and a projector on an adjustable stand were installed as the in‐room visual guidance solution for the closed‐bore ring gantry medical linear accelerator utilized by Ethos. Consistent respiratory motion traces and organ positions on intrafractional CBCTs demonstrated the clinical suitability of the proposed solution in Ethos ART.ConclusionThe study demonstrated the utilization of an institutional visually guided respiratory motion management system for Ethos ART. The proposed solution can be easily applied for Ethos ART and adapted for use with any closed bore‐type system, such as computed tomography and magnetic resonance imaging, through incorporation with appropriate respiratory motion sensors.

Prospective Study of Surface Guided Radiation Therapy (SGRT) for Breath Hold SBRT Treatments of the Lung: Analysis of Reliability of Surface Guidance Alone for Internal Tumor Position During Breath Hold

<h3>Purpose/Objective(s)</h3> Respiratory motion management with breath hold (BH) is one technique to limit normal lung and other organ dose during SBRT treatments of the lung. Surface guidance (SGRT) has been utilized for BH in larger targets such as breast cancer, but its reliability in BH treatments of small targets has not been investigated. We report the initial results of the reliability of utilizing SGRT alone as a technique for BH during a prospective study of treatment of primary and metastatic lung tumors. <h3>Materials/Methods</h3> An IRB approved prospective study was conducted in patients (pts) with primary NSCLC or lung metastasis undergoing SBRT. Eligible pts had at least 1 cm of respiratory associated motion on free breathing 4DCT. Pts underwent planning CT with BH either in end inspiration or expiration per investigator choice. The GTV was contoured on the BH planning CT and a 5mm margin added for PTV expansion. During each SBRT treatment, pts performed BH and were aligned within tolerance based on the reference BH surface capture created from the BH planning CT. Pts underwent short-arc CBCT during BH for volumetric match of the target. Before shifts were made for target match, pts performed a BH within tolerance, then shifts were made prior to a new reference surface capture being immediately obtained during the same BH. Pts were then treated in BH based on the new reference surface with a tolerance of 3mm translations and 2 degree rotations. Treatment was stopped if pts fell outside of the predefined tolerances. Midway through treatment, pts underwent a second short arc CBCT during BH to verify the reliability of target position during BH treatment utilizing SGRT. Any subsequent shifts on target volumetric match after the second CBCT were recorded. Linear mixed models for repeated measures were used to analyze rotational and translational shift measurements. <h3>Results</h3> 13 pts and 39 SBRT fractions were treated utilizing SGRT alone for BH. All pts were treated with 54 Gy in 3 fractions. Median free breathing range of motion (4D ROM) was 1.3 cm. Mean displacements after mid-treatment CBCT were minimal in all directions as shown in Table 1. Only one observed fraction had a displacement that exceeded the 5mm PTV expansion (longitudinal shift of 0.59 cm with resulting vector shift of 0.68cm). Factors evaluated for association with shift magnitude included age, BMI, gender, tumor location, 4D ROM, and GTV and PTV size. Higher 4D ROM was associated with increased longitudinal and vector shifts (<i>P</i> = 0.019 and 0.046). <h3>Conclusion</h3> SGRT provides a reliable technique for BH SBRT treatments of the lung. Minimal target displacements on mid treatment BH CBCT were observed. Higher 4D ROM on free breathing scans correlated with larger displacements in tumor position utilizing this technique.

Reducing the impact on renal function of kidney SABR through management of respiratory motion.

Stereotactic ablative body radiotherapy (SABR) is as a viable treatment option to treat kidney cancer. This study quantifies dose reduction to non-tumour ipsilateral kidney and estimated renal function gain from elimination of respiratory motion. We reviewed 62 previously treated kidney SABR patients. The gross tumour volume (GTV) was segmented in each phase of a four-dimensional CT (4DCT). Tumour motion amplitude (TMA) was obtained from the GTV centroid on each phase. Low modulation, motion managed (MM) plans were generated on the exhale phase image. Internal target volume (ITV)-based plans were generated on the 4DCT average intensity projection. To estimate delivered kidney dose, the ITV-based plan was copied ten times to the exhale phase image, with isocentre located at the GTV centroid position in each phase. The dose was calculated and averaged to result in non-motion managed plans. Difference in ipsilateral kidney volume receiving 50% of the prescription dose (V50%) and estimated glomerular filtration rate (GFR) change were compared between ITV and MM plans. The mean±st.dev. TMA was 0.79±0.49cm. Removing respiratory motion reduced ipsilateral kidney V50% (slope of the difference=12cc/cm of TMA, Pearson-r=0.69, p-value <10-9), and estimated GFR was improved (slope=4.4 %/cm of TMA, Pearson-r=0.85, p-value<10-10). We have quantified the improvement in healthy kidney dose when removing respiratory motion from kidney SABR plans, and demonstrated an expected gain in GFR of 4.4 %/cm of motion removed.

Magnetic resonance imaging with gradient sound respiration guide.

Respiratory motion management is crucial for high-resolution MRI of the heart, lung, liver and kidney. In this article, respiration guide using acoustic sound generated by pulsed gradient waveforms was introduced in the pulmonary ultrashort echo time (UTE) sequence and validated by comparing with retrospective respiratory gating techniques. The validated sound-guided respiration was implemented in non-contrast enhanced renal angiography. In the sound-guided respiration, breathe−in and–out instruction sounds were generated with sinusoidal gradient waveforms with two different frequencies (602 and 321 Hz). Performance of the sound-guided respiration was evaluated by measuring sharpness of the lung-liver interface with a 10–90% rise distance, w10-90, and compared with three respiratory motion managements in a free-breathing UTE scan: without respiratory gating (w/o gating), 0-dimensional k-space navigator (k-point navigator), and image-based self-gating (Img-SG). The sound-guided respiration was implemented in stack-of-stars balanced steady-state free precession with inversion recovery preparation for renal angiography. No subjects reported any discomfort or inconvenience with the sound-guided respiration in pulmonary or renal MRI scans. The lung-liver interface of the UTE images for sound-guided respiration (w10-90 = 6.99 ± 2.90 mm), k-point navigator (8.51 ± 2.71 mm), and Img-SG (7.01 ± 2.06 mm) was significantly sharper than that for w/o gating (17.13 ± 2.91 mm; p < 0.0001 for all of sound-guided respiration, k-point navigator and Img-SG). Sharpness of the lung-liver interface was comparable between sound-guided respiration and Img-SG (p = 0.99), but sound-guided respiration achieved better visualization of pulmonary vasculature. Renal angiography with the sound-guided respiration clearly delineated renal, segmental and interlobar arteries. In conclusion, the gradient sound guided respiration can facilitate a consistent diaphragm position in every breath and achieve performance of respiratory motion management comparable to image-based self-gating.

Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription

AimsTo report late toxicity and long-term outcomes of intensity-modulated radiotherapy (IMRT)-based stereotactic ablative body radiotherapy (SABR) in patients with ultra-central lung tumours. Materials and MethodsThis is a single-institution retrospective analysis of patients treated with SABR for ultra-central tumours between May 2008 and April 2016. Ultra-central location was defined as tumour (GTV) abutting or involving trachea, main or lobar bronchi. Respiratory motion management and static-field dynamic-IMRT were used, with dose prescribed homogeneously (maximum <120%). Descriptive analysis, Kaplan–Meier method, log-rank test and Cox regression were used to assess outcomes. ResultsSixty-five per cent of patients had inoperable primary non-small cell lung cancer and 35% had lung oligometastases. The median age was 72 (range 34–85) years. The median gross tumour volume and planning target volume (PTV) were 19.6 (range 1.7–203.3) cm3 and 57.4 (range 7.7–426.6) cm3, respectively. The most commonly used dose fractionation was 60 Gy in eight fractions (n = 51, 87.8%). Median BED10 for D98%PTV and D2%PTV were 102.6 Gy and 115.06 Gy, respectively. With a median follow-up of 26.5 (range 3.2–100.5) months, fatal haemoptysis occurred in five patients (8.7%), of which two were directly attributable to SABR. A statistically significant difference was identified between median BED3 for 4 cm3 of airway, for patients who developed haemoptysis versus those who did not (147.4 versus 47.2 Gy, P = 0.005). At the last known follow-up, 50 patients (87.7%) were without local recurrence. Freedom from local progression at 2 and 4 years was 92 and 79.8%, respectively. The median overall survival was 34.3 (95% confidence interval 6.1–61.6) months. Overall survival at 2 and 4 years was 55.1 and 41.2%, respectively. ConclusionIn patients with high-risk ultra-central lung tumours, IMRT-based SABR with homogenous dose prescription achieves high local control, similar to that reported for peripheral tumours. Although fatal haemoptysis occurred in 8.7% of patients, a direct causality with SABR was evident in only 3%. Larger studies are warranted to ascertain factors associated with outcomes, especially toxicity, and identify patients who would probably benefit from this treatment.

Ion therapy guideline (Version 2020)

Ion therapy guideline (Version 2020)

Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring

BackgroundStereotactic Ablative Body Radiotherapy (SABR) is a non-invasive treatment which allows delivery of an ablative radiation dose with high accuracy and precision. SABR is an established treatment for both primary and secondary liver malignancies, and technological advances have improved its efficacy and safety. Respiratory motion management to reduce tumour motion and image guidance to achieve targeting accuracy are crucial elements of liver SABR. This phase II multi-institutional TROG 17.03 study, Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring (LARK), aims to investigate and assess the dosimetric impact of the KIM real-time image guidance technology. KIM utilises standard linear accelerator equipment and therefore has the potential to be a widely available real-time image guidance technology for liver SABR.MethodsForty-six patients with either hepatocellular carcinoma or oligometastatic disease to the liver suitable for and treated with SABR using Kilovoltage Intrafraction Monitoring (KIM) guidance will be included in the study. The dosimetric impact will be assessed by quantifying accumulated patient dose distribution with or without the KIM intervention. The patient treatment outcomes of local control, toxicity and quality of life will be measured.DiscussionLiver SABR is a highly effective treatment, but precise dose delivery is challenging due to organ motion. Currently, there is a lack of widely available options for performing real-time tumour localisation to assist with accurate delivery of liver SABR. This study will provide an assessment of the impact of KIM as a potential solution for real-time image guidance in liver SABR.Trial registrationThis trial was registered on December 7th 2016 on ClinicalTrials.gov under the trial-ID NCT02984566.

P20.06 Dosimetric Comparison of the Real and Virtual Plans in Non-Small Cell Lung Cancer Patients Treated With Respiratory Motion Management

We conducted a prospective study to increase tumor control, reducing side effects and dosimetric comparison of the real and virtual plans by using motion management in 40 patients with locally advanced non-small cell lung cancer. The study was approved by the ethics (2018-7/7) and scientific committee (OUAP (T) 2019/2) as scientific research project in our university. Simulation images were obtained using free breathing in the treatment position using axial cine mode 16-slice 4D-CT scanner and RPM in 10 respiratory phases. In the MIP phase, PTV with a 5 mm border in each direction was created for the ITV including the tumor and involved nodes. A volumetric arc treatment plan was established by taking the 98% of prescription dose to 95% of PTV and also taking into account the risky organ doses. Patients were treated with CBCT imaging on LINAC device every other day. For virtual plan, GTV for tumor and involved nodes and CTV according to ICRU83 were created in the free respiratory phase. PTV was created with a 5 mm margin to CTV and virtual treatment plan was created with the same prescribed dose. 10 patients were treated till December 2019. The median age was 59 years (49-72) and the M/F ratio was 8/2. Histopathological diagnosis were SCC (4), adenocarcinoma (5), LCNEC (1). AJCC18 staging were listed as IA2 (1), IIIA (2), IIIB (4), IIIC (2) and IVB (1). The median RT dose was 6300 cGy (5940-6400) with 32 fractions (30-35). In the third month, 2 complete, 3 partial responses and 1 locoregonal progression were detected by PET/CT. ITVtm was 46.98 and GTVtm was 31.27 cc (p = 0.66), while PTV volumes were 173.53 and 494.50 cc (p = 0.008) in treatment and virtual plans, respectively. The tumor volume was higher but PTV volume was lower in the treatment plans. D95 for ITVtm and GTVtm were found 6311 and 6326 cGy (p = 0.72) whereas D95 for PTV 6297 and 6051 cGy (p = 0.13), respectively. The mean lung dose, V5, V20 and V30 were 15.14 vs 16.07 Gy (p = 0.077), 55.95% vs 63.8% (p = 0.087), 26.44% vs 31.55% (p = 0.23) and 17.44% vs 20.64 (p = 0.085), median heart dose was 6.03 and 10.36 Gy (p = 0.043), heart V50 was 8.2% vs 33.9% (p = 0.007), median esophageal dose was 18.94 vs 21.43 Gy (p = 0.35) and esophagus V50 11.39% vs 18% (p = 0.69), the median and maximum spinal cord dose was 8.11 vs 8.22 Gy (p = 0.61) and 33.15 vs 37.39 Gy, respectively (p = 0.22), in treatment and virtual plans. It was observed that all risky organ doses were less in treatment plans than virtual plans with statistical significance in heart doses. In this study, it was shown that the target volume did not increase, the target was covered with 95% accuracy and the risky organ doses were lower in 10 patients who were treated with 4D-CT planning and respiratory motion management.

P20.04 Dosimetric Comparison of the Real and Virtual Plans in Non-Small Cell Lung Cancer Patients Treated With Respiratory Motion Management

P20.04 Dosimetric Comparison of the Real and Virtual Plans in Non-Small Cell Lung Cancer Patients Treated With Respiratory Motion Management

Management of Respiratory Motion in PET/CT: Data-driven Respiratory Gating PET/CT

Management of Respiratory Motion in PET/CT: Data-driven Respiratory Gating PET/CT

Implementation of a visual feedback system for motion management during radiation therapy.

To describe the details of an in-house video goggles feedback system assembled from several commercially available components. The objective of this paper is to share our experience with this system, provide details on the equipment needed, system assembly, patient set up and user settings on some components. The system consisted of goggles (FPView3DHD, ITV, USA), RJ45(Registered Jack) to Digital Visual Interface (DVI) converter (Tripplite), DVI to HDMI converters, Local Area Network(LAN) cable, HDMI and power extender cables. The video coaching system was implemented both in CT simulator (GE Discovery)) and in treatment delivery machine True Beam v2.1 Varian Medical Systems (VMS, Palo Alto), which was integrated with respiratory motion management (RPM V 1.7.5) system. The video feedback system is in clinical use since Aug 2017, so far, we have treated 13 patients, with approximately 150 fractions. The performance of the device was found to be satisfactory. All the patients were coached for DIBH and the usage of the goggles, which includes wearing the goggles, display details of the monitor, and the threshold levels of the breathing wave cycle. The patients understand the instructions very well and hence regulate the breathing cycle, which improves the treatment accuracy and efficiency. Video feedback system for motion management, for patients undergoing radiotherapy was implemented successfully both in CT simulator and in linear accelerator.